<DOC>
	<DOCNO>NCT02871622</DOCNO>
	<brief_summary>Prospective , multi-center , registry design enrol 2,000 patient 35 International center . All patient receive BioMatrix AlphaTM stent per clinical practice follow 2 year data collection . Major adverse cardiac event ( MACE ) result 9 month compare result obtain BioMatrix FlexTM arm LEADERS trial .</brief_summary>
	<brief_title>BMX Alpha Registry : Post-market Registry BioMatrix Alpha TM</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>Patients treat BioMatrix AlphaTM stent per clinical indication physician 's choice ; Patients agree comply follow requirement ; Patients life expectancy &gt; 1 year time consent ; Patients eligible receive dual anti platelet therapy ( DAPT ) accord guideline ; Hemodynamically stable patient . Inability provide informed consent ; Currently participate another trial reach primary endpoint ; Planned surgery within 6 month percutaneous coronary intervention ( PCI ) unless dual antiplatelet therapy maintain throughout perisurgical period ; Patient receive additional stent different BioMatrix AlphaTM stent index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>